An Exploratory Single Site, Open Label, Randomized, Controlled Study to Evaluate Plasma Vascular Endothelial Growth Factor Levels After Intravitreal Injection of Ranibizumab (Lucentis) and Conbercept (Langmu) for nAMD
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Ranibizumab (Primary) ; Conbercept
- Indications Wet age-related macular degeneration
- Focus Pharmacodynamics
- Acronyms RELIANCE
- Sponsors Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
Most Recent Events
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
- 01 Aug 2016 Status changed from recruiting to completed.
- 04 May 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016.